RE: So sad.25 Jun 2022 08:01
''The Board intends to work with the Joint Administrators on proposals to rescue the Company as a going concern, albeit there can be no guarantee that this will be successful.''
Its 'only' $13m. In the grand scheme that's not much. Additional funding would obviously be required for continued research/operation.
Yes, any II buyer, such as Merck potentially, would no doubt use the situation to their great advantage and offer low, but there are possibilities. Oxford, for whatever reason, want their money back, no doubt not helped by Duncan's investor event performance. Biotech is back on the up so there may be more interest now. Do Merck want to take the chance of someone else buying this in admin? Who knows. There is plenty of value (IP/research/expertise/production) left in this company. Definitely not clutching at straws, in my mind the money has gone, just my own thoughts, nothing more.